Business View Magazine | March 2019

257 tion here inside of 2019, after the legislative session ends in June.” BVM: Who will be the typical customer or end user? Moran: “Parallel to developing the actual prod- uct, we were developing our core brand mes- saging. It’s a statistical fact that 87 percent of all medical decisions are made by the female lead in the family. So that’s who we targeted. The product is built as serious medical with the downstream of a lifestyle brand, and pri- mal branding has been aimed at a 28 and older, affluent female demographic, toward biopharmaceuticals and nutraceuticals – those are the families we’re initially targeting and then expanding from there. “We have several partners in the medical com- munity. Across the two companies, we have a total of 29 hard-money investors and several of those are physicians. We recently had a commitment from one of them to help us write the documentation for our child’s autistic trial, so we can take that to the next step. In addi- tion, Dr. Brian Tarbet, a biochemist, and a valu- able part of our R&D team, is currently helping us finalize a pain cream topical.” BVM: What are your biggest challenges going forward for 2019? Moran: “Definitely, legislative. We’re starting to